Without a doubt, 2020 has been a trying year. The pandemic has touched every business and every human on earth in different ways. And despite all of its tragic outcomes, it has starkly reminded me that we work in one of the most exciting and innovative industries in the world — the life sciences industry.
I am writing this at a time when the US FDA has just issued an emergency use authorization for a vaccine using new technology, against a new pathogen. We are also just days away from another potential FDA vaccine approval. All of this happened in only a few months and it’s remarkable. …
I recently authored an article for MedCity News discussing the hype surrounding AI, especially as it relates to fighting COVID-19. Since the very beginning of this pandemic, researchers and pharmaceutical companies have been working around the clock to find treatments and, more importantly, develop a vaccine. And, as usual, there has been a plethora of media articles and peer-reviewed journal publications discussing how AI can support these efforts. A lot of that is driven by AI companies themselves, or companies that apply AI to discover treatments.
When this virus became a serious public threat at the beginning of this year, multiple AI companies shifted their focus to using AI to fight coronavirus and their approaches are varied, ranging from drug repurposing to finding novel molecules. But, as I have stated in my article, what we need is the wide availability of safe and effective vaccines. AI is not the key to achieving this goal. …
by: Aaron Daugherty
This week we are celebrating the release of the 250th version of our drug discovery software platform! I am so incredibly proud of the improvements our software team is constantly pushing out; it is the foundation that supports twoXAR’s dedication to rapidly identifying treatments for patients in need.
Our platform makes drug discovery and development faster and with fewer false positives. To build this platform, we use an approach that tightly couples scientists and software developers to make R&D faster, more accurate, and/or cheaper. Our scientists work with our software team to share how they work through specific processes and in turn, our developers build software solutions to help address the biggest hurdles in those processes. …
I met Tim for the first time almost three years ago and I remember our meeting well. He furrowed his brow slightly as I explained the details on how our technology creates computational models of pathogenesis to derive new understanding of disease, and then identifies hits to test those new hypotheses within weeks instead of years. I’ve come to learn that the furrowed brow appears when the gears start turning in Tim’s head. And what exceptional gears they are.
Today I received an email from an influencer in the life science community. Paraphrasing a bit, here’s what she said:
“We have reviewed nearly 400 companies in this space — so much going on! How are you differentiated from others?”
Rather than email her individually, I viewed this as the perfect opportunity to share how twoXAR Pharmaceuticals is different. Our work is like nothing else.
We are a pharmaceutical company that uses AI in the discovery of new medications
To begin to answer the question we must start with differentiating ourselves against the hundreds of companies using AI in life sciences. These companies cover everything from anatomy to zoology and everything in between. While there are parallels to our work in these areas, we differentiate ourselves from the broad spectrum of AI life science companies with our focus: We are a pharmaceutical company. …
As usual, there’s a lot of news coming out of the 38th Annual JPMorgan Chase Healthcare Conference. And machine learning’s ability to support the pharmaceutical research and development process is no exception. There have been dozens of presentations on this very topic, and even more companies pitching the promise of artificial intelligence (AI). But, one thing is very clear: More education is needed about how AI can support pharmaceutical research.
The JPMorgan Chase conference is centrally a finance and investor meeting. And what we’ve seen so far is that healthcare investors continue to bet on AI startups at an unprecedented rate. This trend is not slowing. However, from our vantage point, there are few companies that employ an approach that has high potential to find new treatments, and more importantly that considers the unique needs of biotech and pharma companies. …
Nine new projects, three announced partnerships
Like many of you, I am winding down my work week to prepare for the holiday season. As a new decade approaches it is a good time to reflect on the events of the past year.
2019 saw tremendous growth for twoXAR. We launched nine new disease areas, expanding to new disease programs in our focus areas of ophthalmology, immunology & inflammatory, oncology and metabolic. We ended the year with eighteen total diseases in our portfolio, six of which have been out licensed.
As with other transformative technologies, expectations will be raised, lowered, dashed and restored before AI shows its real value
Since co-founding twoXAR five years ago, I have consistently held the same beliefs about AI’s role in drug discovery, and I’ve delivered a consistent message about it. The world’s reaction to my words has evolved, from skepticism to curiosity to full-blown excitement.
Many believe AI is the panacea that will revolutionize the healthcare industry, and dollars are flowing into healthcare AI startups at unprecedented rates as investors make big bets on using the technology to analyze health data, improve efficiency in healthcare delivery, speed drug discovery, and offer new therapies for intractable diseases. …
Five years ago my namefellow, Andrew A. Radin (twoXAR CEO), and I launched twoXAR to apply new technology to discovering medicines for patients with unmet medical needs. Over the years we developed our 3P strategy (platform, process, portfolio) which I am confident is the most efficient, lowest risk, and highest probability path to success in today’s world of drug development.
After careful consideration and planning I’ve decided now is the right time for me to transition to an advisory role at twoXAR. To implement the 3P strategy we’ve built an exceptional team of scientists, engineers, and business professionals that continues to develop and broaden month over month. …